Corline Biomedical AB - Asset Resilience Ratio

Latest as of December 2025: 20.85%

Corline Biomedical AB (CLBIO) has an Asset Resilience Ratio of 20.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Corline Biomedical AB PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr20.56 Million

≈ $2.21 Million USD Cash + Short-term Investments

Total Assets

Skr98.58 Million

≈ $10.61 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Corline Biomedical AB's Asset Resilience Ratio has changed over time. See CLBIO net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Corline Biomedical AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Corline Biomedical AB.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr20.56 Million	20.85%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr20.56 Million	20.85%

Asset Resilience Insights

Good Liquidity Position: Corline Biomedical AB maintains a healthy 20.85% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Corline Biomedical AB Industry Peers by Asset Resilience Ratio

Compare Corline Biomedical AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Corline Biomedical AB (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Corline Biomedical AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	20.85%	Skr20.56 Million ≈ $2.21 Million	Skr98.58 Million ≈ $10.61 Million	+2.21pp
2024-12-31	18.64%	Skr17.67 Million ≈ $1.90 Million	Skr94.76 Million ≈ $10.20 Million	+1.65pp
2023-12-31	16.99%	Skr17.01 Million ≈ $1.83 Million	Skr100.11 Million ≈ $10.77 Million	-8.76pp
2022-12-31	25.75%	Skr26.21 Million ≈ $2.82 Million	Skr101.78 Million ≈ $10.95 Million	-15.20pp
2021-12-31	40.95%	Skr41.63 Million ≈ $4.48 Million	Skr101.66 Million ≈ $10.94 Million	+26.09pp
2020-12-31	14.86%	Skr8.66 Million ≈ $932.28K	Skr58.28 Million ≈ $6.27 Million	-20.99pp
2019-12-31	35.85%	Skr22.86 Million ≈ $2.46 Million	Skr63.75 Million ≈ $6.86 Million	-8.09pp
2018-12-31	43.94%	Skr27.64 Million ≈ $2.97 Million	Skr62.91 Million ≈ $6.77 Million	+11.16pp
2017-12-31	32.78%	Skr16.86 Million ≈ $1.81 Million	Skr51.43 Million ≈ $5.53 Million	+4.03pp
2016-12-31	28.74%	Skr11.86 Million ≈ $1.28 Million	Skr41.27 Million ≈ $4.44 Million	--

pp = percentage points

About Corline Biomedical AB

ST:CLBIO Sweden Biotechnology

Market Cap

$48.93 Million

Skr454.64 Million SEK

Market Cap Rank

#22035 Global

#414 in Sweden

Share Price

Skr17.75

Change (1 day)

-0.84%

52-Week Range

Skr10.00 - Skr21.20

All Time High

Skr28.20